» Articles » PMID: 11861388

The CC Chemokine RANTES in Breast Carcinoma Progression: Regulation of Expression and Potential Mechanisms of Promalignant Activity

Overview
Journal Cancer Res
Specialty Oncology
Date 2002 Feb 28
PMID 11861388
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer progression may be affected by various cellular components expressed by the tumor cells and/or by microenvironmental factors. Many studies report the correlation between breast cancer progression and monocyte infiltration into the tumor site. We have identified recently the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, as a potential contributor to breast cancer progression. In the present study, analysis of the regulation of RANTES expression demonstrates that the expression of RANTES in breast tumor cells is elevated significantly and in a synergistic manner by IFN-gamma and tumor necrosis factor-alpha. Identification of the mechanisms by which RANTES may contribute to breast cancer progression included the analysis of the potential ability of RANTES to act in paracrine and indirect mechanisms, as well as directly on the tumor cells, to promote disease progression. Our results suggest that breast tumor cell-derived RANTES may promote breast cancer progression by its partial contribution to monocyte migration into breast tumor sites. Moreover, RANTES promotes the expression of matrix metalloproteinase (MMP) 9 by THP-1 monocytic cells and elevates vascularity in chick chorioallantoic membrane assays. Tumor necrosis factor-alpha, a major monocyte-derived cytokine, was found to promote the expression of MMP9 and MMP2 by MCF-7 and T47D breast adenocarcinoma cells, respectively, and to induce the de novo expression of an additional proteolytic enzyme by T47D cells, presumably MMP9. The possibility that RANTES may act directly on breast tumor cells was supported by detection of the expression of the CCR5 RANTES receptor in biopsy sections of breast cancer patients and by the ability of RANTES to promote the expression of MMP9 by MCF-7 cells. In all, our study suggests that the expression of RANTES by breast tumor cells results not only in monocyte migration to the tumor site but also in protumorigenic activities of RANTES and of proinflammatory cytokines that may facilitate metastasis formation and contribute to disease progression.

Citing Articles

Fatty Degenerative Osteonecrosis of the Jaw: Bridging Molecular Insights and Clinical Practice-A Scoping Review.

Dominiak M, Niemczyk W, Pitulaj A, Swienc W, Matys J Int J Mol Sci. 2025; 26(5).

PMID: 40076479 PMC: 11899097. DOI: 10.3390/ijms26051853.


Road traffic noise and breast cancer: DNA methylation in four core circadian genes.

Thacher J, Snigireva A, Dauter U, Delaval M, Oudin A, Mattisson K Clin Epigenetics. 2024; 16(1):168.

PMID: 39587706 PMC: 11590349. DOI: 10.1186/s13148-024-01774-z.


Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics.

Somu P, Basavegowda N, Gomez L, Jayaprakash H, Puneetha G, Yadav A Biomedicines. 2023; 11(10).

PMID: 37893013 PMC: 10604354. DOI: 10.3390/biomedicines11102639.


Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy.

Chen W, Chang T, Chou H, Cheng M, Hong J, Hsieh Y Int J Mol Sci. 2023; 24(11).

PMID: 37298699 PMC: 10253890. DOI: 10.3390/ijms24119748.


Autophagy modulators influence the content of important signalling molecules in PS-positive extracellular vesicles.

Hanelova K, Raudenska M, Kratochvilova M, Navratil J, Vicar T, Bugajova M Cell Commun Signal. 2023; 21(1):120.

PMID: 37226246 PMC: 10210466. DOI: 10.1186/s12964-023-01126-z.